139 related articles for article (PubMed ID: 7552742)
1. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
[TBL] [Abstract][Full Text] [Related]
2. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Petitou M; van Boeckel CA
Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
[TBL] [Abstract][Full Text] [Related]
3. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
[TBL] [Abstract][Full Text] [Related]
4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
5. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
[TBL] [Abstract][Full Text] [Related]
6. Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.
Chen Y; Lin L; Agyekum I; Zhang X; St Ange K; Yu Y; Zhang F; Liu J; Amster IJ; Linhardt RJ
J Pharm Sci; 2017 Apr; 106(4):973-981. PubMed ID: 28007564
[TBL] [Abstract][Full Text] [Related]
7. Novel approach for preparation of heparins specific to factor Xa using affinity chromatography coupled with synthetic antithrombin III-related peptides.
Onoue S; Harada S; Nemoto Y; Yajima T; Kashimoto K
Peptides; 2003 Jun; 24(6):821-6. PubMed ID: 12948833
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of heparin-dependent thrombin and factor Xa inhibitory activities of antithrombin-III by mutations in the reactive site.
Theunissen HJ; Dijkema R; Grootenhuis PD; Swinkels JC; de Poorter TL; Carati P; Visser A
J Biol Chem; 1993 Apr; 268(12):9035-40. PubMed ID: 8473344
[TBL] [Abstract][Full Text] [Related]
9. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex.
Berry L; Stafford A; Fredenburgh J; O'Brodovich H; Mitchell L; Weitz J; Andrew M; Chan AK
J Biol Chem; 1998 Dec; 273(52):34730-6. PubMed ID: 9856996
[TBL] [Abstract][Full Text] [Related]
11. Synthetic heparin derivatives as new anticoagulant drugs.
de Kort M; Buijsman RC; van Boeckel CA
Drug Discov Today; 2005 Jun; 10(11):769-79. PubMed ID: 15922935
[TBL] [Abstract][Full Text] [Related]
12. Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A; Petitou M
Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
[TBL] [Abstract][Full Text] [Related]
13. New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
Petitou M; Duchaussoy P; Driguez PA; Hérault JP; Lormeau JC; Herbert JM
Bioorg Med Chem Lett; 1999 Apr; 9(8):1155-60. PubMed ID: 10328304
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins.
Paiva JF; Santos EA; Jeske W; Fareed J; Nader HB; Dietrich CP
Comp Biochem Physiol A Physiol; 1995 Jul; 111(3):495-9. PubMed ID: 7614042
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of thrombin inactivation by immobilized heparin.
Byun Y; Jacobs HA; Kim SW
J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
[TBL] [Abstract][Full Text] [Related]
16. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
[TBL] [Abstract][Full Text] [Related]
17. [Anticoagulant activity of fucoidans from brown algae].
ushakova NA; Morozevich GE; Ustiuzhanina NE; Bilan MI; Usov AI; Nifant'ev NE; Preobrazhenskaia ME
Biomed Khim; 2008; 54(5):597-606. PubMed ID: 19105402
[TBL] [Abstract][Full Text] [Related]
18. Human antithrombin III-derived heparin-binding peptide, a novel heparin antagonist.
Onoue S; Nemoto Y; Harada S; Yajima T; Kashimoto K
Life Sci; 2003 Oct; 73(22):2793-806. PubMed ID: 14511765
[TBL] [Abstract][Full Text] [Related]
19. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
